Age-related and fibrotic diseases deserve better treatments
Fibrotic diseases affect millions of people a year. Today’s anti-fibrotic therapies slow progression by targeting broad fibroblast and inflammation pathways, but none directly clear the cells at the root of the disease.
Many of these diseases share a fundamental pathobiology: the accumulation of senescent cells. As the body ages, these cells secrete inflammatory factors into surrounding tissue, causing fibrotic scarring and blocking the body’s natural ability to clear ageing cells.
Our goal is to direct the immune system to counteract age-related tissue decline.
A computational platform that maps the surfaceome of fibrotic tissues
The historical barrier to the effective treatment of age-related and fibrotic disease has been a lack of precision.
Neotis has developed NTS, a computational platform that identifies highly specific transmembrane targets unique to ageing and damaged tissues.
A proven modality, better targets
Immunotherapy has already made once-incurable diseases treatable. Neotis builds on that foundation in target discovery, target validation, and therapeutic development.
We are starting with idiopathic pulmonary fibrosis, a fatal disease with no cure and a pressing need for therapies that address its cause rather than its symptoms.
